<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B675829B-3A07-47C2-AA9F-86C9F86DD6A6"><gtr:id>B675829B-3A07-47C2-AA9F-86C9F86DD6A6</gtr:id><gtr:name>Scottish Universities Life Sciences Alliance (SULSA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C5F16D4F-F1DA-459E-B344-DC54C5E90C44"><gtr:id>C5F16D4F-F1DA-459E-B344-DC54C5E90C44</gtr:id><gtr:name>Jefferson Medical College</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B675829B-3A07-47C2-AA9F-86C9F86DD6A6"><gtr:id>B675829B-3A07-47C2-AA9F-86C9F86DD6A6</gtr:id><gtr:name>Scottish Universities Life Sciences Alliance (SULSA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C5F16D4F-F1DA-459E-B344-DC54C5E90C44"><gtr:id>C5F16D4F-F1DA-459E-B344-DC54C5E90C44</gtr:id><gtr:name>Jefferson Medical College</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B4B2F9EB-1720-4668-A2F8-1D80C795707F"><gtr:id>B4B2F9EB-1720-4668-A2F8-1D80C795707F</gtr:id><gtr:firstName>Valerie</gtr:firstName><gtr:surname>Brunton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9026D809-A3A5-407F-9EBB-CFA20FD6CEAB"><gtr:id>9026D809-A3A5-407F-9EBB-CFA20FD6CEAB</gtr:id><gtr:firstName>Tessa</gtr:firstName><gtr:surname>Holyoake</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0600782"><gtr:id>A9016A99-357D-4E50-B83C-7E45D2CC6C33</gtr:id><gtr:title>Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600782</gtr:grantReference><gtr:abstractText>CML has an incidence of 1.3 per 100,000 of the population with 750 new cases per year in the UK. CML begins when a stem or founder bone marrow cell develops a genetic change during division. This change results in the Philadelphia chromosome and the Bcr-Abl cancer protein being found in all CML cells, including the stem cells. The Bcr-Abl protein is an enzyme called a tyrosine kinase and tyrosine kinase inhibitors (TKIs) have now been introduced for the treatment of CML. Imatinib mesylate (IM), the first of these drugs to reach the clinic, is now the standard of care for 85% of CML patients in the early stages of the condition. When started at diagnosis this drug has induced remission in 80% of cases, leading to absence of the Ph chromosome, and has reduced the annual rate of progression from 10-15%, before the introduction of IM, to only 2-4%, with patients now expected to survive at least 10 years from diagnosis and possibly much longer. However IM does not cure CML and all patients still have CML stem cells present. We have recently shown that the amount of Bcr-Abl cancer protein is greatly increased in CML stem cells and we were the first to show that CML stem cells are resistant to killing by IM. Our current work is investigating whether IM, or new generation stronger TKIs, achieve high enough levels inside the CML stem cells to effectively overcome the very high levels of cancer protein and whether drug pumps, on the surface of CML stem cells, limit the build up of these drugs inside cells. The question we wish to address in this proposal is whether the activity (whether it is on or off) of the Bcr-Abl cancer protein is the major determinant of whether these stem cells survive and divide to sustain leukaemia in patients or undergo a process called programmed cell death when the protein is switched off. We are confident we have the expertise to investigate and answer this question. If CML stem cell survival does not require Bcr-Abl to be on at all times then we need to develop new approaches, other than TKIs, to kill these cells. Our overall aim is to understand what keeps CML stem cells alive and find new ways to kill these cells so that patients may be cured and come off all drug therapies.</gtr:abstractText><gtr:technicalSummary>Chronic myeloid leukaemia (CML) arises in a haemopoietic stem cell targeted by the t(9;22)/Ph translocation. Although all Ph+ cells express Bcr-Abl transcripts and oncoprotein, we have recently shown both mRNA and oncoprotein to be greatly overexpressed at the stem cell level. Bcr-Abl is a constitutively active tyrosine kinase and a number of tyrosine kinase inhibitors (TKIs) have now been introduced for the treatment of CML. We were the first to show that CML stem cells are inherently insensitive to imatinib mesylate (IM), the first of these agents to reach the clinic. Furthermore, IM does not eradicate CML stem cells in vivo and the majority of patients have residual disease as detected by RT-PCR for Bcr-Abl transcripts. Our current work has investigated whether IM, or more potent TKIs, achieve high enough intracellular levels within CML stem cells to effectively inhibit the upregulated levels of oncoprotein and the role that influx and efflux drug pumps play in determining intracellular drug accumulation. The key question that will be addressed here is whether Bcr-Abl activity is relevant for survival of CML stem cells. One hypothesis is that by inhibiting Bcr-Abl in a stem cell you simply revert the malignant phenotype to normal. The alternative hypothesis is that at the time the stem cell acquires t(9;22), additional changes occur that confer a survival advantage and the cell becomes dependent on Bcr-Abl expression. We are now confident we have the expertise to investigate and answer this question. We will use alternative but complementary approaches. Primary CD34+ CML cells will be exposed to TKIs in vitro with surviving stem cells tracked over time, at the single cell level, for inhibition of Bcr-Abl activity, apoptosis, retention of primitive phenotype and function and proliferation. To maximise Bcr-Abl inhibition at the stem cell level the above approach will be combined with lentiviral delivered shRNA against Bcr-Abl. Finally to demonstrate the effect of Bcr-Abl inhibition within transplantable stem cells in vivo, a transgenic model that expresses Bcr-Abl from a tetracycline responsive element driven by the SCL3? enhancer (to allow induced expression of Bcr-Abl in the stem cell compartment), will be employed. If CML stem cell survival is proven to be independent of Bcr-Abl, then alternative approaches to selectively target and eradicate the cancer stem cell pool will be required. For example, these might exploit Bcr-Abl expression to facilitate delivery of a cytotoxic agent selectively to Ph+ CML cells.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-10</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-03-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>588175</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Beatson Institute for Cancer Research</gtr:department><gtr:description>CRUK</gtr:description><gtr:id>62084EC9-C33D-43B6-BE96-F48B2ED55C89</gtr:id><gtr:impact>Nothing as yet</gtr:impact><gtr:partnerContribution>Providing LC3-GFP mouse to cross to BCR-ABL double transgenic mouse. Ed Chan is providing expertise relating to ULK-1</gtr:partnerContribution><gtr:piContribution>We are the leaders of partnership</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London (UCL), UCL Cancer Institute</gtr:department><gtr:description>autophagy work</gtr:description><gtr:id>F23196DE-1844-4BAB-B8FE-2FA050124735</gtr:id><gtr:impact>19363292</gtr:impact><gtr:partnerContribution>Collaborated on paper - Pubmed reference 19363292</gtr:partnerContribution><gtr:piContribution>We have generated a new grant entitled &amp;quot;A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR&amp;quot; MRC Ref: G0900882</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish Universities Life Sciences Alliance (SULSA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SULSA</gtr:description><gtr:id>947142B0-90BE-4081-BF1D-5C78D2E028AF</gtr:id><gtr:impact>Still awaitng</gtr:impact><gtr:partnerContribution>Ed Chan is providing expertise relating to ULK-1</gtr:partnerContribution><gtr:piContribution>We are the leaders of the partnership</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>Paolo Salmoni</gtr:description><gtr:id>04E667A5-8AB7-4B5F-BBF2-9A4FC60E1181</gtr:id><gtr:impact>JCI paper
Kay kendall grant
MRC grant
MRC DGT</gtr:impact><gtr:partnerContribution>enhanced science</gtr:partnerContribution><gtr:piContribution>we published the JCI paper together</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jefferson Medical College</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Cancer Biology</gtr:department><gtr:description>Bruno Calabretta</gtr:description><gtr:id>0006B8D2-D371-4E5E-A8BC-11EF6C5354D3</gtr:id><gtr:impact>JCi paper
Kay Kendall grant
MRC grant
MRC DGT sponsorship</gtr:impact><gtr:partnerContribution>ENHANCED RESEARCH</gtr:partnerContribution><gtr:piContribution>published JCI paper together</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thomas Jefferson University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>autophagy work</gtr:description><gtr:id>A077E558-40AF-4C66-9BF8-D7F6A0802F56</gtr:id><gtr:impact>19363292</gtr:impact><gtr:partnerContribution>Collaborated on a paper - Pub med reference 19363292</gtr:partnerContribution><gtr:piContribution>We have generated a new grant entitled &amp;quot;A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR&amp;quot; MRC Ref: G0900882</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ESH Vienna</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E03065C5-47C6-4682-BF71-4CD591AEE48A</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BUSCC University Stem cell seminar Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7F0B5D2-79C2-4382-9ADD-0C74A20433AC</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Haematology - Brighton</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DE18022-218D-40C0-B3DB-8AEA6B9B2EC6</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paterson Institute Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DF1FBCC7-D87E-4365-945F-23249A5A0D1C</gtr:id><gtr:impact>talk

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>lecture tour Canada</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E68DC69-AF17-420C-B755-3EF9AF934E0F</gtr:id><gtr:impact>9 lectures in Montreal, Ottawa, Toronto, Hamilton between 8-11 Sept 2008, medical staff, students, nurses

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCMLSG Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3A195CBE-B053-4CDB-AE02-F6583E4142F5</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Australia Directors in Leukaemia Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CE5431B2-BCFE-4C9E-9EBC-C86CFF4F710D</gtr:id><gtr:impact>audience 200, mix of scientists and medics,45 minutes

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCSF Cancer Centre, San Francisco</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F69CEDE2-CAB4-4A61-BAA4-2D3B4828E4D0</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TSCRC Dundee</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F352CD9-E801-4EAF-8E35-19BCFC819794</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISEH Amsterdam</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EA2B8859-19D2-405A-AE7A-68A9F6DC085C</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quarterley Divisional newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2E21B4A4-288A-4F42-AB32-DEBDCF829ECB</gtr:id><gtr:impact>Update with all grants and papers

Information circulated to all scientists within division</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beatson Institute, Cancer School, Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BC7978F0-E971-4613-85EB-9F6B6E53544A</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>French Haematology group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0A83618-E9E2-49F0-AD02-8128F95453FD</gtr:id><gtr:impact>audience of 120, French haematologists and clinical trial co-ordinators, 30 minutes

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Baltimore</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>734C7727-931B-4BD0-93A5-A6F89354B042</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CML Professionals Meeting Newcastle</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C750A45C-F83B-42B6-BF46-E2CB65DC5034</gtr:id><gtr:impact>CML Professionals Meeting

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C443BD0E-B749-4722-A0C3-CC845E306B86</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>retiral lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>43BD708E-B1D0-4192-8DE5-64D4031C6A27</gtr:id><gtr:impact>audience around 80, local cytogenetics department for retiral of member of staff

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Haematology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>46CBC319-F5EE-4F8A-B314-4EACCFA90DBD</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3455EE44-13B3-4570-A980-D794F137EA98</gtr:id><gtr:impact>500 audience, CML research and clinical run by ESH

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASH San Diego</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>08B924BA-5F16-4A37-959F-94FEE9610B7D</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LRF one off meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5EB6924-D324-44A4-9DCD-1C02C21FB752</gtr:id><gtr:impact>around 200, scientist and medical staff, 25 minutes,

press release</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA Milan</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7010E376-2043-4402-B7F2-F6B3ED793A4A</gtr:id><gtr:impact>talk with discussion

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Erasmus Haematology Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB177120-3DF7-4857-A2F3-52EDD44ECB60</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beatson Institute for Cancer Research, Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>554203C0-10DD-4292-BF88-2A40102CB213</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKNSCN 4th Annual science meeting York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AE2C5932-3015-4BA2-8728-8AF63F2519AE</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCMLSG Seminar Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>403C3B95-8D24-4B2A-B1DE-4E1B07857302</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South East Scotland Blood Club meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4B27A94F-7AFF-4F7A-A58B-68C2721E0C2A</gtr:id><gtr:impact>talk

opened up discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>4th International Workshop on CML, Natchez</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BC95692D-844E-4809-8BB4-B9643FDD4F30</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Third Global Workshop on CML, New Orleans</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>581985B4-0846-44EA-ADD2-33AF12AEA675</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>open days for new paul O'Gorman Leukaemia Research centre</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B93E32A7-9367-485C-BC88-7ECBFB323167</gtr:id><gtr:impact>9/10 and 22 May 2008. Audience of around 100 at each, short speeches, poster presentations, demon strations in the laboratory

press were present - Sunday Times, Herald articles guest of honour Richard Rockefeller</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paterson Institute Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EE3504BF-4CD2-460F-B94D-A70DC7255E17</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCSF Cancer Centre, San Francisco</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2AE73389-FF2C-4BE7-A87B-1DE4B7E04F51</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LR, GHD London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B59080FB-DAAB-4E29-BB1F-A414F9AAA58D</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH-CML Bordeaux</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0AA3FDF3-9CF2-4208-8C29-788B45ADBBEB</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA/ESH Cancer Stem cell workshop, Cannes, France</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1F6EFA7A-AC5F-45FF-8762-E08512485C5F</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cancer Research Award Symposium, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>63A76ABF-9118-4B66-B197-AB0619DC079F</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA meeting London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>19ADE3DA-2400-4ECA-933D-24D45E49B0D8</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI annual meeting Birmingham</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>49955DE7-3ACD-4FF7-942C-5F632694CAF4</gtr:id><gtr:impact>2-300, oncologists, haematologists, public, patients, nurses, pharmacists etc

did a report for press</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA Amsterdam</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0508ED0A-ABFB-4543-87C9-B0CE08BD7981</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leukaemia and cancer stem cells workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>58F165DE-9171-4417-A16D-D2FB070187A4</gtr:id><gtr:impact>small workshop only 23, biologists, computer modellers, mathematicians

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E15D72FA-AE96-4714-A785-9FB44ED7C63D</gtr:id><gtr:impact>audience of 25, short speeches and lab demonstrations

press release</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Vienna Cancer Stem Cell Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6E062970-4159-4FB5-A19C-BC3BDE84A5B7</gtr:id><gtr:impact>100, scientists and medical staff

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Portugal</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D00BB8F9-0A71-414E-9DF2-B90B7B6AF3B9</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BUSCC University Stem Cell seminars birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4023DC15-634E-41A6-A3DF-7F451A30227C</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wilsede cancer stem cells meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2F81466-0436-4F11-93A9-EA111C986716</gtr:id><gtr:impact>audience 200, students, scientists, medical staff, interactive,

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2042F0BD-87C3-4280-84AA-7459D90FD6D7</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AAAS Vancouver</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6294A238-34FC-4ACF-BD23-40F011C2FB00</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKNSCN York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBE16979-79A8-4B33-BA55-B8347044910A</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beatson Institute for Cancer Research Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4C914DF8-D086-40B9-81F7-57D640A69CF4</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>330216</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>0AA9E758-D751-4713-94A8-F1316D98E928</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novartis</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>0AC5C01D-0F65-4570-9C66-AFA865320A4F</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833326</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Trial Grant (A randomised phase 2 trial of IM versus HCQ/IM with CML in MCyR with residual disease by Q-PCR)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>23605709-ACC2-4160-BBE0-17011AE44CAA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant</gtr:description><gtr:end>2020-05-02</gtr:end><gtr:fundingOrg>Bloodwise</gtr:fundingOrg><gtr:id>2DAE948B-925A-4E40-BC15-485EBD30F9C0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19980</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A1657502-48C9-4CE4-8B9A-D9CF3C2CD710</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>6585EBDB-98A0-4E58-8AB0-B1AE3DBB3CF7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SULSA</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:fundingRef>MSD23_G_Holyoake-Chan</gtr:fundingRef><gtr:id>F5DB9368-E237-4E36-828F-40833244DC7A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>training of basic pHd and clinical research fellows</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>A335E455-A9F1-4794-B663-6B2E2556F56C</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9D07F17-0256-4D4C-8379-1CE7D061A820"><gtr:id>F9D07F17-0256-4D4C-8379-1CE7D061A820</gtr:id><gtr:title>Targeted therapy in haematological malignancies.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a870925ac016ad80b9494e829a777bce"><gtr:id>a870925ac016ad80b9494e829a777bce</gtr:id><gtr:otherNames>Hamilton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9D23825-9FFB-4AF8-B524-88105AC0C22C"><gtr:id>A9D23825-9FFB-4AF8-B524-88105AC0C22C</gtr:id><gtr:title>Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6FA1333-ABD7-4FEC-A0CF-C9336FB591C2"><gtr:id>C6FA1333-ABD7-4FEC-A0CF-C9336FB591C2</gtr:id><gtr:title>Autophagy in blood cancers: biological role and therapeutic implications.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42679940e74537b9b3b7b8e59ac8c0ba"><gtr:id>42679940e74537b9b3b7b8e59ac8c0ba</gtr:id><gtr:otherNames>Nencioni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69B3CD86-9D3E-47E7-9F3B-89CB035FC2A7"><gtr:id>69B3CD86-9D3E-47E7-9F3B-89CB035FC2A7</gtr:id><gtr:title>Casting a NETwork instead of shooting magic bullets.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44701d76135ad7a45126aa81a11d96bc"><gtr:id>44701d76135ad7a45126aa81a11d96bc</gtr:id><gtr:otherNames>Abraham SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB2438E5-4161-4D9A-B7B1-08F520C534E5"><gtr:id>FB2438E5-4161-4D9A-B7B1-08F520C534E5</gtr:id><gtr:title>Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b2818ed3e00fce516b946caeaff33806"><gtr:id>b2818ed3e00fce516b946caeaff33806</gtr:id><gtr:otherNames>Scott MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C51F162-AED1-452D-9EBC-0D8017A99357"><gtr:id>3C51F162-AED1-452D-9EBC-0D8017A99357</gtr:id><gtr:title>NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d260fdf9797851668913497ea5b8373b"><gtr:id>d260fdf9797851668913497ea5b8373b</gtr:id><gtr:otherNames>Chen CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FDEED2F-092D-4ABF-BD7E-6F6CB21CA108"><gtr:id>6FDEED2F-092D-4ABF-BD7E-6F6CB21CA108</gtr:id><gtr:title>Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d42fb6e14192ab57f136b2127cd541f"><gtr:id>8d42fb6e14192ab57f136b2127cd541f</gtr:id><gtr:otherNames>Lipka DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB4495A4-1EBA-4CFB-9226-A408F0F26DC3"><gtr:id>BB4495A4-1EBA-4CFB-9226-A408F0F26DC3</gtr:id><gtr:title>Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/361dca97f7a514271678ccfdbd37f88a"><gtr:id>361dca97f7a514271678ccfdbd37f88a</gtr:id><gtr:otherNames>Elling C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B44AD9DA-49FE-4757-B056-70A8B970B1D3"><gtr:id>B44AD9DA-49FE-4757-B056-70A8B970B1D3</gtr:id><gtr:title>BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05db6288d2e0904e1ef010bbffd9500a"><gtr:id>05db6288d2e0904e1ef010bbffd9500a</gtr:id><gtr:otherNames>Schemionek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08434C5F-9460-44FB-80D2-088F7536D6DD"><gtr:id>08434C5F-9460-44FB-80D2-088F7536D6DD</gtr:id><gtr:title>Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy.</gtr:title><gtr:parentPublicationTitle>Current cancer drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/01722AAA-A239-4362-BC4D-E75A0E51A414"><gtr:id>01722AAA-A239-4362-BC4D-E75A0E51A414</gtr:id><gtr:title>Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC2447AE-4F37-47D3-958A-8775E7E0C143"><gtr:id>CC2447AE-4F37-47D3-958A-8775E7E0C143</gtr:id><gtr:title>Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1448bee0ae56bd58fecff6db43339f5"><gtr:id>a1448bee0ae56bd58fecff6db43339f5</gtr:id><gtr:otherNames>Bellodi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/649BBACC-821F-42E0-8977-93B5BDF638A0"><gtr:id>649BBACC-821F-42E0-8977-93B5BDF638A0</gtr:id><gtr:title>Stem Cell Guardians - Old and New Perspectives in LSC Biology.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b63b5b65b3097b2a5034c842ad8f951"><gtr:id>7b63b5b65b3097b2a5034c842ad8f951</gtr:id><gtr:otherNames>Horne GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96D7D8F9-AC6A-4E52-BBAD-0BF31F795366"><gtr:id>96D7D8F9-AC6A-4E52-BBAD-0BF31F795366</gtr:id><gtr:title>ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E32F8C5-916D-4AF2-B8CF-8CD574CE3A35"><gtr:id>4E32F8C5-916D-4AF2-B8CF-8CD574CE3A35</gtr:id><gtr:title>Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a870925ac016ad80b9494e829a777bce"><gtr:id>a870925ac016ad80b9494e829a777bce</gtr:id><gtr:otherNames>Hamilton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB32CB99-05BB-468F-8BE3-F17CEC621C01"><gtr:id>EB32CB99-05BB-468F-8BE3-F17CEC621C01</gtr:id><gtr:title>Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a870925ac016ad80b9494e829a777bce"><gtr:id>a870925ac016ad80b9494e829a777bce</gtr:id><gtr:otherNames>Hamilton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2966EC9C-E716-4E14-933C-3CF86479DA58"><gtr:id>2966EC9C-E716-4E14-933C-3CF86479DA58</gtr:id><gtr:title>ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F643536F-9609-4CE8-8406-57E6249CBCB0"><gtr:id>F643536F-9609-4CE8-8406-57E6249CBCB0</gtr:id><gtr:title>The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86e6f4cc5f28e75d0ac2d7d32e30b8fc"><gtr:id>86e6f4cc5f28e75d0ac2d7d32e30b8fc</gtr:id><gtr:otherNames>Pellicano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4BBA5B23-2793-4FD5-A1CE-73F584145F34"><gtr:id>4BBA5B23-2793-4FD5-A1CE-73F584145F34</gtr:id><gtr:title>Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0adffa95b98009b59dbbff5ad48a307"><gtr:id>e0adffa95b98009b59dbbff5ad48a307</gtr:id><gtr:otherNames>Myssina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/01AE4A3F-5F5A-4885-B804-2C996B2A446F"><gtr:id>01AE4A3F-5F5A-4885-B804-2C996B2A446F</gtr:id><gtr:title>Do we need more drugs for chronic myeloid leukemia?</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9971b356a7b47c06716ecaedfc78dca8"><gtr:id>9971b356a7b47c06716ecaedfc78dca8</gtr:id><gtr:otherNames>Holyoake TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4FB943CC-3CCB-46B3-BC19-6AC67CEFF940"><gtr:id>4FB943CC-3CCB-46B3-BC19-6AC67CEFF940</gtr:id><gtr:title>Mtss1 is a critical epigenetically regulated tumor suppressor in CML.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05db6288d2e0904e1ef010bbffd9500a"><gtr:id>05db6288d2e0904e1ef010bbffd9500a</gtr:id><gtr:otherNames>Schemionek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F34A3303-D8F3-452A-AF2A-717A65525AC2"><gtr:id>F34A3303-D8F3-452A-AF2A-717A65525AC2</gtr:id><gtr:title>Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44701d76135ad7a45126aa81a11d96bc"><gtr:id>44701d76135ad7a45126aa81a11d96bc</gtr:id><gtr:otherNames>Abraham SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00B78046-4F95-4329-A0F9-1E66C3BB3F82"><gtr:id>00B78046-4F95-4329-A0F9-1E66C3BB3F82</gtr:id><gtr:title>Preclinical approaches in chronic myeloid leukemia: from cells to systems.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1aeabcd4ae4e875e598fdac6506e39c8"><gtr:id>1aeabcd4ae4e875e598fdac6506e39c8</gtr:id><gtr:otherNames>Clarke CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08B554DD-6181-4AC6-A48E-0AD5BFA19E0A"><gtr:id>08B554DD-6181-4AC6-A48E-0AD5BFA19E0A</gtr:id><gtr:title>Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?</gtr:title><gtr:parentPublicationTitle>Expert review of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71f27e4858bd91991e7a007ab35ab9ea"><gtr:id>71f27e4858bd91991e7a007ab35ab9ea</gtr:id><gtr:otherNames>Mukhopadhyay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1747-4094</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A91CE277-46A5-479D-84EB-2E7897375E70"><gtr:id>A91CE277-46A5-479D-84EB-2E7897375E70</gtr:id><gtr:title>The chronic myeloid leukemia stem cell: stemming the tide of persistence.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9971b356a7b47c06716ecaedfc78dca8"><gtr:id>9971b356a7b47c06716ecaedfc78dca8</gtr:id><gtr:otherNames>Holyoake TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF79C3DC-B95A-4256-B2E0-C1F741A1D257"><gtr:id>EF79C3DC-B95A-4256-B2E0-C1F741A1D257</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA445E6C-5E54-44E1-8E05-EA26897D91C2"><gtr:id>CA445E6C-5E54-44E1-8E05-EA26897D91C2</gtr:id><gtr:title>Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/357e346840a75f26dc84314d035a8560"><gtr:id>357e346840a75f26dc84314d035a8560</gtr:id><gtr:otherNames>Allan EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8160A7B4-A52F-4E40-83EF-DF214B5BBB6D"><gtr:id>8160A7B4-A52F-4E40-83EF-DF214B5BBB6D</gtr:id><gtr:title>CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b8e937115ca36efe414c34a2b80c707"><gtr:id>9b8e937115ca36efe414c34a2b80c707</gtr:id><gtr:otherNames>Sinclair A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F085B836-ADD8-4596-B876-64F5D7D399BF"><gtr:id>F085B836-ADD8-4596-B876-64F5D7D399BF</gtr:id><gtr:title>Role of autophagy in cancer prevention, development and therapy.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/806F075D-B5A9-4695-8538-F3D7E9FB0650"><gtr:id>806F075D-B5A9-4695-8538-F3D7E9FB0650</gtr:id><gtr:title>Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05db6288d2e0904e1ef010bbffd9500a"><gtr:id>05db6288d2e0904e1ef010bbffd9500a</gtr:id><gtr:otherNames>Schemionek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600782</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>